ROCHESTER, MN, December 9th, 2020 – The innovative animal health biotechnology company, LEAH Labs, has raised over $359,000 on its Wefunder crowdfunding campaign. This brings their total financing to date to nearly $700,000. The Wefunder campaign is open through February 20th. More information can be found at www.wefunder.com/LEAH.
Equity crowdfunding is a new form of investing that follows the models of public support for companies and ideas popularized by sites like Indiegogo, Kickstarter, and GoFundMe. However, unlike those sites where they offer deals on new products or chances to support charitable causes in exchange for support, equity crowdfunding allows those who want to support a company to invest money and receive equity. This allows anyone to become an investor in an idea, team, and company they believe in. Equity crowdfunding investors get returns on their investments if companies they invest in do well in the future, just like any traditional angel investor or investment firm.
Of the ongoing Wefunder campaign, Dr. Wierson said “Wefunder offers an amazing new way for the general public to get involved in early stage companies like ours. Raising on Wefunder not only shows there is grassroots support for our mission, but even sophisticated angel investors have found us and invested because of the reach of a Reg CF deal. Over ⅓ of the 89,000,000 dogs in the USA will get cancer, and with dogs being part of the family, they deserve cutting edge medical treatments just like us humans. We’ve already received tremendous support from people whose furry family members have suffered from cancer, and their stories motivate us to keep fighting this fight.”
This seed round will allow LEAH Labs to optimize and scale their technology, file for new intellectual property, and begin initial trials in dogs for their first therapeutic by the end of 2020.
LEAH Labs is building cures for cancer in dogs. They use modern gene editing technologies to make living cell therapies, like CAR-T cell therapy, accessible and affordable to the veterinary market. Based on new treatments in humans that can provide curative outcomes in the clinic today, they are first developing a treatment for the canine analog of human non-Hodgkin’s lymphoma, B cell lymphoma. Learn more at www.leahlabs.com
Wes Wierson, PhD
email@example.com or 515-979-9851